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ABSTRACT.
Purpose: To indirectly measure stromal riboﬂavin penetration using commer-
cially available riboﬂavin solutions and new and existing epithelium-oﬀ, trans-
epithelial and iontophoresis-assisted delivery protocols.
Methods: Forty porcine eyes were divided into eight groups. Group 1: Ricrolin
applied to the de-epithelialised cornea for 30 min; Group 2: epithelium-intact, no
treatment; Groups 3–5: epithelium-intact, 30-min application of Ricrolin TE,
Mediocross TE or ParaCel/Vibex, respectively. Group 6: epithelium-intact,
Ricrolin+ iontophoresis-assisted delivery for 5 min; Group 7: epithelium-intact,
Ricrolin+ iontophoresis-assisted delivery for 5 min with a 20-min riboﬂavin
soak; and Group 8: epithelium-intact, Ricrolin+ iontophoresis-assisted delivery
for 5 min, 15-min soak and another 5 min of iontophoresis. After a saline wash,
light transmission spectra were obtained from each cornea, before and after
epithelial removal.
Results: Corneas in groups 1 and 8 showed a distinct riboﬂavin absorption peak
between 400 and 520 nm. The optical density of the corneas in groups 3–7 did
not diﬀer signiﬁcantly from that of the untreated corneas (group 2).
Conclusions: A modiﬁcation to the standard iontophoresis trans-epithelial
technique resulted in successful penetration of riboﬂavin into the stroma and
appears to oﬀer the most promise for epithelium-on cross-linking.
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Introduction
Riboﬂavin/ultravioletA (UVA) 370 nm
radiation corneal cross-linking (CXL)
has become increasingly popular as a
means of stabilizing corneas that have
been biomechanically weakened by dis-
ease or refractive surgery (Wollensak
et al. 2003). The basis for this therapy
lies in the knowledge that the incidence
of naturally occurring cross-links within
the corneal macromolecules increases
with age, resulting in progressive tissue
stiﬀening (Elsheikh et al. 2007). Fur-
thermore, keratoconus, a condition
characterized by thinning and weaken-
ing of the cornea, rarely progresses
beyond the age of 40 (Olivares Jimenez
et al. 1997) and is less prevalent among
patients with diabetes due to the accel-
eration of the glycation cross-linking
process (Mohammad et al. 2014). It was
postulated that artiﬁcial cross-linking
using riboﬂavin and UVA 370 nm radi-
ation could induce a similar stiﬀening
eﬀect, particularly in conditions such as
keratoconus, where the collagen archi-
tecture within the corneal stroma is
susceptible to enzymatic degradation
(Kenney et al. 1994; Sawaguchi et al.
1994) and ﬁbrillar slippage (Meek et al.
2005;Hayes et al. 2007). Clinical studies
of CXL, with follow-up times of up to
6 years, have shown it to be an eﬀective
means of halting keratoconus progres-
sion in over 90% of cases (Raiskup-
Wolf et al. 2008; O’Brart et al. 2013)
with minimal reports of complications
(Meek & Hayes 2013) and no change in
corneal drug permeability following
treatment (Tapeiner et al. 2014).
Despite being a relatively noninvasive
and safe procedure, the standard CXL
protocol requires removal of the central
7–9 mm of the corneal epithelium, prior
to instillation of a hyperosmolar ribo-
ﬂavin solution and exposure to UVA
irradiation (Wollensak et al. 2003). In
an attempt to speed visual rehabilitation
and reduce both the postoperative
patient discomfort (Ghanem et al.
2013) and the risk of infection associated
with epithelial debridement (Sharma
et al. 2010), the concept of trans-epithe-
lial stromal riboﬂavin delivery has
become increasingly popular and
prompted research into alternative
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means of riboﬂavin delivery without the
need for epithelial removal. However,
the diﬃculty in delivering riboﬂavin
across an intact corneal epithelium was
evident in such research from the outset
as riboﬂavin is a large hydrophilic
molecule (molecular weight 340 Da)
and the lipophilic epithelium has a
decreasing permeability to molecules
over 180 Da (Huang et al. 1989). Our
previous spectrophotometry investiga-
tions into the eﬀectiveness of complete
epithelial removal versus partial epithe-
lial disruption or the application of 20%
alcohol or 1% tetracaine to loosen the
epithelial tight junctions prior to the
application of dextran-enriched riboﬂa-
vin solution showed that a suﬃcient and
homogenous stromal uptake of riboﬂa-
vin could only be achieved by complete
removal of the epithelial barrier (Hayes
et al. 2008; Samaras et al. 2009).
Recently, transepithelial riboﬂavin
solutions have been developed which
claim to facilitate the passage of ribo-
ﬂavin across the intact epithelium. The
majority of these solutions are dextran
free [with the exception of Ricrolin TE
(Sooft Italia S.p.A., Montegiorgio,
Italy)], on the basis that the high molec-
ular weight of dextran is believed to
inhibit the penetration of riboﬂavin
across the epithelium (Huang et al.
1989; Hayes et al. 2008; Wollensak &
Iomdina 2009). In the dextran-free trans-
epithelial solutions, hydroxypropyl
methycellulose (HPMC) is often used as
a riboﬂavin vehicle and additional chem-
ical agents, such as benzalkonium chlo-
ride (BAC), ethylenediamine tetra-acetic
acid (EDTA) and tometamol (Tris), are
added to enhance the penetration of
riboﬂavin through the corneal epithe-
lium into the stroma(Ramselaar et al.
1988). The use of iontophoresis-assisted
riboﬂavin delivery, in which a low-
intensity electrical current is used to
drive the negatively charged, water-sol-
uble riboﬂavin molecules through the
corneal epithelium, is also being
explored.
Although trans-epithelial CXL
undoubtedly oﬀers patients a less
invasive treatment than the standard
epithelium-oﬀ technique and thereby
facilitates the treatment of paediatric
and unco-operative patients, as well
those with very thin corneas, its
eﬀectiveness remains uncertain (Lec-
cisotti & Islam 2010; Caporossi et al.
2012; Filippello et al. 2012; Bouher-
aoua et al. 2014). As riboﬂavin is
essential to the CXL process, acting
both as a photosensitizer for the
production of oxygen free radicals to
activate cross-link formation and as
an absorber of UVA radiation to
prevent damage to internal ocular
structures, the eﬀectiveness of the
therapy is dependent on adequate
stromal riboﬂavin uptake.
In this study, we use spectropho-
tometry to indirectly measure and
compare stromal riboﬂavin penetration
in ex vivo porcine corneas following
the standard (epithelium-oﬀ) protocol,
four clinically available trans-epithelial
riboﬂavin delivery protocols and two
modiﬁed iontophoretic protocols.
Methods
Samples and treatments
Forty porcine eyes with intact corneal
epitheliums were transported on ice
from a local abattoir within 4 hr of
death. On arrival, the corneas were
randomly and equally divided into the
eight treatment groups described below
and summarized in Table 1:
(1) Epithelium-removed riboﬂavin
delivery (epi-oﬀ, Ricrolin): Following
complete debridement of a central
10 mm area of corneal epithelium with
a scalpel blade, riboﬂavin eye drops
containing 0.1% riboﬂavin and 20%
dextran T500 (Ricrolin, Sooft Italia
S.p.A., Montegiorgio, Italy) were
applied for 30 min.
(2) Epithelium-intact, untreated con-
trols (Epi-on, no Tx)
(3) Ricrolin trans-epithelial riboﬂavin
delivery (Epi-on, Ricrolin TE): Ricro-
lin TE (Sooft Italia S.p.A., Montegior-
gio, Italy) was applied to the anterior
surface of epithelium-intact corneas for
30 min, followed by a 2-min 0.9%
saline rinse.
(4) Mediocross trans-epithelial riboﬂa-
vin delivery (Epi-on, Mediocross TE):
Mediocross TE (Peschke GmbH,Wald-
shut-Tiengen, Germany) was applied to
the anterior surface of epithelium-intact
corneas for 30 min. This was followed
by a 2 min 0.9% saline rinse.
(5) Paracel/Vibex trans-epithelial ribo-
ﬂavin delivery (Epi-on, ParaCel/
Vibex): ParaCel (Avedro, Waltham,
MA, USA) was applied to the anterior
surface of epithelium-intact corneas for
4 min. This was followed by the appli-
cation of Vibex Xtra (Avedro, Wal-
tham, MA, USA) for a further 6 min
and then a 2-min 0.9% saline rinse.
(6) Ricrolin+ trans-epithelial, ion-
tophoresis-assisted riboﬂavin delivery
(Epi-on, Ricrolin+ and Ionto): Ricro-
lin+ ((Sooft Italia S.p.A.,Montegiorgio,
Table 1. Summary of treatments and riboﬂavin composition.
Group Type and composition of riboﬂavin solution used Epi on/oﬀ Stromal delivery method Treatment Abbreviation
1 Ricrolin: 0.1% riboﬂavin, 20% dextran, puriﬁed water Oﬀ Direct application Epi-oﬀ, Ricrolin
2 N/A On N/A Epi-on, No Tx
3 Ricrolin TE: 0.1% riboﬂavin, 15% dextran, Tris,
EDTA, puriﬁed water
On Trans-epithelial Epi-on, Ricrolin TE
4 Mediocross TE: 0.25% riboﬂavin, 1.2% HPMC, 0.01%
BACS, Pi-water
On Trans-epithelial Epi-on, Mediocross TE
5 ParaCel: riboﬂavin 0.25%, HPMC, BACS, NaCl,
EDTA, Tris.
Vibex Xtra: 0.22% riboﬂavin, NaCl
On Trans-epithelial Epi-on, Paracel/Vibex
6 Ricrolin+: 0.1% riboﬂavin, Tris, EDTA, puriﬁed water On Trans-epithelial/iontophoresis
assisted
Epi-on, Ricrolin+ and Ionto
7 Ricrolin+: 0.1% riboﬂavin, Tris, EDTA, puriﬁed water On Trans-epithelial/iontophoresis
assisted (with 20 min soak time)
Epi-on, St Thomas’/
Cardiﬀ Ionto A
8 Ricrolin+: 0.1% riboﬂavin, Tris, EDTA, puriﬁed water On 2 9 trans-epithelial/ionto-phoresis
assisted (with 15 min soak time)
Epi-on, St Thomas’/
Cardiﬀ Ionto B
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Italy) was delivered trans-epithelially by
means of 1 mA iontophoresis for 5 min
(total charge of 300 mC). The ion-
tophoresis delivery system was used to
treat ex vivo eyes by connecting the
return electrode to a needle inserted into
the vitreous chamber; the negative elec-
trode was a steel grid contained in a
corneal well applicator which was
adhered to the eye bymeans of a vacuum
system (Fig. 1). The steel grid (negative
electrode) was completely covered with
riboﬂavin and thepower generator set to
the desired current and duration. The
steel grid remained covered with ribo-
ﬂavin solution for the entire procedure.
After treatment, the applicator was
removed from the cornea and the cornea
was rinsed with 0.9% saline solution for
2 min.
(7) Modiﬁed Ricrolin+ trans-epithe-
lial, iontophoresis-assisted riboﬂavin
delivery (Epi-on, St Thomas’/Cardiﬀ
Ionto A): Ricrolin+ was delivered
trans-epithelially by means of 1 mA
iontophoresis for 5 min (total charge
of 300 mC) and left in situ for a 20-min
soak time. Following treatment, the
cornea was washed with 0.9% saline
solution for 2 min.
(8) Modiﬁed Ricrolin+ trans-epithe-
lial, iontophoresis-assisted riboﬂavin
delivery (Epi-on, St Thomas’/Cardiﬀ
Ionto B): Ricrolin+ was delivered
trans-epithelially by means of 1 mA
iontophoresis for 5 min and a 15-min
riboﬂavin soak, followed by 0.5 mA
iontophoresis for 5 min (total charge
of 450 mC). After treatment, the cor-
nea was washed with 0.9% saline
solution for 2 min.
Riboﬂavin solutions were adminis-
tered by means of a suction ring (with
vacuum syringe) designed for CXL and
LASEK procedures which adhered to
the corneal surface (e.Janarch srl,
Como, Italy). Although the corneas in
this study were not exposed to UVA,
every attempt was made to mimic the
clinical riboﬂavin application proce-
dure. On the basis that riboﬂavin
accumulation within the epithelium
could cause UVA absorption and
reduce the dosage of UVA to the
stroma, a 2-min post-treatment saline
rinse was performed on each cornea in
groups 3–8 to remove riboﬂavin from
the intact epithelium. It was not neces-
sary to perform a saline rinse on
corneas is group 1 (as the epithelium
was removed) or group 2 (as no
riboﬂavin was applied).
Data collection
Central corneal thickness measure-
ments were recorded immediately fol-
lowing treatment using a Pachette2TM
Ultrasonic Pachymeter (DGH Tech-
nology, Exton, PA, USA). The cornea
with a 3-mm scleral rim was then
surgically dissected from the globe
and placed into a sample holder
(Fig. 2). The natural curvature of the
cornea was maintained by clamping the
scleral rim within the sample holder
and injecting silicon oil (Dow Corning
200/5cS, BDH Laboratory Supplies,
Poole, UK) into the chamber behind
it. Silicon oil was also injected into the
front chamber of the holder so as to
maintain a uniform refractive index
and reduce light scatter (Kostyuk et al.
2002). The sample holder was then
positioned into a specially adapted
PYE Unicam (Cambridge, UK) SP8-
100 UV/VIS spectrophotometer with a
1-mm circular beam, in such a way that
light passed through the centre of the
cornea in the anterior–posterior direc-
tion. A transmission spectrum was
measured for each cornea at 10-nm
intervals within the range of 400–
700 nm and in the case of the epithe-
lium-intact control and treated corneas
(groups 2, 3, 4, 5, 6, 7 and 8), a second
spectrum and corneal thickness mea-
surement was recorded from each spec-
imen following epithelial removal. A
further transmission spectrum was
obtained for riboﬂavin solution alone.
As the process of treating and col-
lecting data from forty corneas took
12 hr to complete and progressive
swelling of the cornea occurs with
increasing time post-mortem, it was
necessary to avoid hydration bias
between treatment groups. This was
ensured by treating and examining the
corneas in ﬁve batches, with each batch
containing a single cornea from each
treatment group.
To normalize the corneal data dur-
ing the analysis process, baseline read-
ings from the sample holder ﬁlled only
with silicon oil were recorded over the
same wavelength range (400–700 nm)
before each corneal measurement.
Spectrophotometric data analysis
As we have previously shown (Hayes
et al. 2008), one of the absorption
peaks of riboﬂavin is evident at 400–
520 nm (Fig. 3A). To evaluate the
relative amount of riboﬂavin within
the cornea following each treatment,
the light transmission data for each
cornea were ﬁrst normalized against its
baseline reading. This was performed
by expressing the light transmission
Posi ve electrode
(steel needle 
inserted into the
vitreous chamber)
Nega ve electrode (steel grid)
covered in riboflavin
Corneal applicator held in 
place by a vacuum suc on 
system
ti
Fig. 1. Iontophoresis riboﬂavin delivery system modiﬁed for use in ex vivo eyes.
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measurements as a ratio of the trans-
mission recorded from each cornea
(mounted in a silicon oil ﬁlled cham-
ber) to the baseline reading obtained
from the same chamber ﬁlled only with
silicon oil. The normalized light trans-
mission measurements for individual
corneas were then converted into
absorbance (optical density) values,
which were averaged together for each
treatment group and plotted against
wavelength. The corneal data were
then isolated between 400 and 520 nm
to facilitate the detection of diﬀerences
in riboﬂavin absorption between indi-
vidual corneas (before and after epithe-
lial removal) and between corneas in
diﬀerent treatment groups. In order to
further isolate the absorption caused
by riboﬂavin, it was necessary to
remove a background of scattering
and absorption arising from the cornea
itself. This was performed by selecting
points on either side of the riboﬂavin
peak and then ﬁtting (Fig. 3B) and
removing a power law background
(Fig. 3C).
Statistical analysis
As a means of making direct compar-
isons between treatments groups (in
terms of riboﬂavin uptake), the absorp-
tion at 450 nm (in the middle of the
riboﬂavin peak) was examined statisti-
cally by means of ANOVA and post hoc
least signiﬁcant diﬀerence testing.
Fig. 2. Sample holder used for spectrophotometry studies. After mounting the cornea on the
sample platform, the anterior clamp is positioned to form a tight seal around the tissue. Silicon oil
is then injected on either side of the cornea, ﬁrst into the posterior chamber of the holder (A), to
maintain the natural curvature of the cornea, and then into the anterior chamber (B).
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Fig. 3. An average optical density spectrum from riboﬂavin-treated corneas. (A) The region of absorption due to riboﬂavin (between 400 and
520 nm) is highlighted in grey. By isolating the riboﬂavin peak and ﬁtting and subtracting a power law background (dashed line) arising from the
optical density of the cornea itself (B), the absorption due to the presence of riboﬂavin within the tissue could be assessed (C) and compared between
treatment groups.
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Results
Corneal thickness
Figure 4 shows the average post-treat-
ment corneal thickness for each group.
The epi-oﬀ, Ricrolin-treated corneas
(group 1) were signiﬁcantly thinner (by
approximately 280 lm) than all the
epithelium-intact treated (groups 3–8)
and untreated (group 2) corneas
(p < 0.001). The average thickness of
the trans-epithelial treated corneas in
groups 3–5 and the trans-epithelial-
and iontophoresis-treated corneas in
groups in 6–8 did not diﬀer signiﬁ-
cantly from that of the epithelium-
intact, untreated corneas in group 2,
which had an average thickness of
853 lm.
Optical density: evaluation of stromal
riboﬂavin uptake
Figure 5 shows photographs of each
treated and untreated cornea, recorded
immediately post-treatment and again
after epithelial removal. The distinctive
yellow coloration of riboﬂavin was
most evident in the epithelium-oﬀ
treated corneas (group 1) and the
epithelium-intact, St Thomas’/Cardiﬀ
Ionto B-treated corneas (group 8). In
contrast, the coloration of corneas
treated trans-epithelially with either
Ricrolin TE (group 3) or ParaCel/
Vibex (group 5) was similar to that of
the untreated corneas (group 2), thus
indicating little or no penetration of
riboﬂavin into either the epithelium or
stroma. Corneas treated with Medio-
cross TE (group 4), Ricrolin+ and
iontophoresis (group 6) and the St
Thomas’/Cardiﬀ Iontophoresis proto-
col A (group 7) showed some evidence
of riboﬂavin penetration immediately
post-treatment, but the yellow col-
oration (indicating the presence of
riboﬂavin) appeared to diminish after
the removal of the epithelium.
Figure 6A shows the post-treatment
variation in the optical density spectra
of corneas treated with diﬀerent ribo-
ﬂavin delivery protocols alongside the
optical density spectra obtained from
untreated corneas. Although the ribo-
ﬂavin peak (between 400 and 520 nm)
is the most obvious feature in Fig. 5,
an additional peak is evident at around
400–420 nm. This peak may corre-
spond to cytochrome C absorption
(Kostyuk et al. 2002) and could there-
fore be an indication of cell death. In
treatments which have resulted in sig-
niﬁcant riboﬂavin uptake (groups 1, 4,
6–8), this additional peak is less evi-
dent, presumably because the riboﬂa-
vin peak masks the eﬀect of
cytochrome C.
As a means of making direct com-
parisons between treatment groups (in
terms of riboﬂavin uptake), the absorp-
tion at 450 nm was examined post-
treatment and following removal of the
epithelium (Table 2 and Fig. 6). As
would be expected, the optical density
was lowest in the epithelium-intact,
untreated corneas (group 2) (as no
riboﬂavin was applied) and greatest in
the epithelium-removed, riboﬂavin-
treated corneas (as riboﬂavin was
absorbed directly into the corneal
stroma). The optical density in the
epi-oﬀ, riboﬂavin-treated corneas
(group 1) was signiﬁcantly higher than
that of all other untreated (group 2),
trans-epithelial (groups 3–5)- and ion-
tophoresis (groups 6–8)-treated cor-
neas (p < 0.01).
The optical density of the Ricrolin
TE (group 3)-, Mediocross TE (group
4)- and ParaCel/Vibex (group 5)-trea-
ted corneas did not diﬀer signiﬁcantly
from that of the untreated corneas
(group 2) before or after epithelial
removal, indicating that these proto-
cols resulted in minimal uptake of
riboﬂavin into either the epithelium or
the stroma. Although not statistically
signiﬁcant, corneas treated with
Ricrolin+ + ionto (group 6) and St
Thomas’/Cardiﬀ Ionto protocol A
(group 7) tended to have a higher
optical density than the untreated and
non-iontophoresis-assisted trans-ep-
ithelial treated corneas.
The St Thomas’/Cardiﬀ-modiﬁed
iontophoresis protocol B (group 8)
appeared to be the only eﬀective
epithelium-intact method of delivering
riboﬂavin to the corneal stroma as,
unlike all the other trans-epithelial
treatments tested, it resulted in signif-
icantly higher optical density values at
450 nm than the untreated corneas
(p < 0.01). The optical density of the
St Thomas’/Cardiﬀ-modiﬁed ion-
tophoresis protocol B-treated corneas
was higher than the untreated corneas
when measured immediately post-treat-
ment (p < 0.01) and similarly, when
measured after removal of the epithe-
lium (p < 0.01), thus indicating the
successful penetration of riboﬂavin
across the epithelial barrier into the
stroma.
Discussion
Adequate stromal riboﬂavin uptake is
essential to the CXL process as it acts
as a photosensitizer to trigger cross-
link formation during UVA exposure
and increases UVA absorption within
the cornea, aﬀording protection to
internal ocular structures, such as the
endothelium, lens and retina (Wollen-
sak et al. 2003; Spoerl et al. 2007). In
this study, spectrophotometry was used
to assess stromal riboﬂavin uptake and
compare the eﬀectiveness of the stan-
dard, epithelium-oﬀ delivery technique
to that of new and existing trans-
epithelial techniques.
The thickness of corneas treated
with trans-epithelial riboﬂavin solu-
tions, either with or without ion-
tophoresis, did not diﬀer from that of
epithelium-intact untreated corneas,
but the de-epithelialized corneas trea-
ted with the standard hyperosmolar
riboﬂavin solution containing 20%
dextran were found to be signiﬁcantly
thinner. Although the removal of the
epithelium may account for up to 35%
of this reduction in corneal thickness,
857
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Fig. 4. Post-treatment corneal thickness (SD).
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based on the porcine epithelium mea-
suring approximately 90 lm, the
remainder may be attributed to the
presence of dextran which creates a
high osmotic pressure gradient that
drives water from the cornea (Hamaoui
et al. 2001). A decrease in corneal
thickness following application of sim-
ilar hyperosmolar riboﬂavin solutions
has been seen previously in vitro in
porcine corneas (Kling et al. 2010) and
clinically in humans (Kymionis et al.
2009). Furthermore, 15% and 20%
dextran solutions are known to eﬀec-
tively dehydrate de-epithelialized
donor eye bank corneas to physiolog-
ical thickness (Hamaoui et al. 2001).
Although Ricrolin TE contains 15%
dextran, it was found to have no
signiﬁcant eﬀect on corneal thickness,
likely as a consequence of the limited
penetration of large dextran molecules
across an intact corneal epithelium
(Huang et al. 1989; Hayes et al. 2008;
Wollensak & Iomdina 2009). This idea
was supported by the fact that the
optical density in our Ricrolin TE-
treated corneas did not diﬀer signiﬁ-
cantly from that of the untreated
corneas, indicating that there was
Fig. 5. Photographs of treated and untreated corneas captured before (Epi-on) and after (Epi-oﬀ) epithelium removal. All treatment abbreviations
are detailed in Table 1.
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minimal uptake of riboﬂavin, and
therefore dextran, into either the
epithelium or the stroma. Published
clinical studies also indicate limited
stromal riboﬂavin penetration in eyes
treated with Ricrolin TE in the pres-
ence of an intact epithelium; the treat-
ment has been shown to result in a
much shallower ‘demarcation line’ (oc-
curring at depths of ~100 lm), than
seen following the standard epithelium-
oﬀ CXL, where the demarcation line
reaches 330 lm (Filippello et al. 2012).
It has been postulated that this
‘demarcation line’, which is clearly seen
2–6 weeks afterCXLon slit-lampbiomi-
croscopy and optical coherence tomog-
raphy, represents the eﬀective depth of
cross-linking (Seiler & Hafezi 2006;
Kymionis et al. 2014), although more
research is needed to ascertain its true
relationship to the actual CXL process.
The clinical results obtained follow-
ing trans-epithelial CXL with Ricolin
TE (Sooft Italia trans-epithelial CXL
protocol) are varied. One study of 20
patients reported a cessation in kerato-
conus progression and an improvement
in topographic and visual parameters
at 18-month follow-up (Filippello et al.
2012). However, another similar sized
study with 24-month follow-up showed
limited stabilization of keratoconus
after 12 months, with 50% of cases
requiring epithelium-oﬀ retreatment
due to progression (Caporossi et al.
2012). In a recently published random-
ized controlled study, comparing
Ricrolin TE trans-epithelial CXL with
the standard epithelium-oﬀ technique,
whilst safety with this trans-epithelial
protocol was excellent, 23% of eyes
showed evidence of progression at
12 months, compared to stabilization
in all eyes treated with standard epithe-
lium-oﬀ CXL (Soeters et al. 2015).
Such ﬁndings suggest limited eﬃcacy
with this trans-epithelial protocol,
which is likely to be a result of limited
riboﬂavin stromal absorption.
Similar to the Sooft Italia trans-
epithelial CXL protocol (Ricrolin TE),
we found that the Peschke trans-ep-
ithelial protocol (Mediocross TE) and
the Avedro trans-epithelial protocol
(Paracel/Vibex) also resulted in mini-
mal epithelial and stromal riboﬂavin
uptake. This suggests that neither the
removal of dextran from the riboﬂavin
formulation nor the addition of Tris,
EDTA, sodium chloride and BACS are
suﬃcient to signiﬁcantly enhance the
penetration of riboﬂavin across an
intact epithelium. In accordance with
this, a recent study examining epithelial
integrity following various trans-ep-
ithelial protocols found Ricrolin TE
and Paracel/Vibex to result in the least
disruption to the corneal epithelium
(Taneri et al. 2014). Whilst to date
there have been no published clinical
trials examining the eﬀectiveness of the
Mediocross or Paracel/Vibex proto-
cols, on the basis of our results and
published studies using Ricrolin TE, we
suspect that eﬃcacy will be limited
compared to the standard epithelium-
oﬀ technique.
Although not statistically signiﬁcant,
corneas treated with the Sooft ion-
tophoresis-assisted delivery protocol
(Ricrolin+ and ionto) and the St
Thomas’/Cardiﬀ-modiﬁed iontophoresis-
assisted protocol A tended to have
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Fig. 6. The averaged optical density of untreated corneas (epi-on, no Tx) and corneas treated with a range of riboﬂavin delivery protocols (as detailed
in Table 1) are shown immediately post-treatment (A) and after post-treatment removal of the epithelium (B).
Table 2. The eﬀect of treatment and de-epithelialization on the average (SD) optical density at
450 nm.
Optical density
Post-treatment Postepithelium removal
(1) Epi-oﬀ, Ricrolin 0.272  0.087a 0.272  0.087f
(2) Epi-on, no Tx 0.011  0.003b,c 0.009  0.002g,h
(3) Epi-on, Ricrolin TE 0.015  0.009b,e 0.006  0.01g,j
(4) Epi-on, Mediocross TE 0.039  0.029b,e 0.023  0.01g,j
(5) Epi-on, ParaCel/Vibex 0.026  0.01b,e 0.016  0.016g,j
(6) Epi-on, Ricrolin+ and Ionto 0.067  0.046b,e 0.056  0.045g,j
(7) Epi-on, St Thomas’/Cardiﬀ Ionto A 0.067  0.038b,e 0.061  0.035g,j
(8) Epi-on, St Thomas’/Cardiﬀ Ionto B 0.149  0.066b,d 0.135  0.063g,i
Statistical diﬀerences between epithelium-intact and epithelium-removed treated and untreated
corneas: a,b and f–g: p < 0.001; c,d and h,i: p < 0.01; and c–e and h–j showed no signiﬁcant
diﬀerence.
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higher optical density values than
untreated and non-iontophoresis-as-
sisted trans-epithelial treated corneas.
This is consistent with the ﬁndings of
Mastropasqua et al. (2014); using
human cadaver eyes and high-perfor-
mance liquid chromatography, they
showed that trans-epithelial ion-
tophoresis-assisted delivery resulted in
a greater and deeper riboﬂavin satura-
tion than Ricrolin TE treatment alone
but could not match the standard epi-
oﬀ technique in terms of stromal
riboﬂavin concentration. Furthermore,
clinical examination of 30 patients’ eyes
revealed the presence of a signiﬁcantly
shallower and less visible demarcation
line in trans-epithelial treated corneas
(Ricolin+ and iontophoresis) than in
standard epithelium-oﬀ cross-linked
corneas (Bouheraoua et al. 2014).
In contrast to all other trans-epithe-
lial riboﬂavin delivery protocols tested
in this study, the St Thomas’/Cardiﬀ
Iontophoresis protocol B resulted in
signiﬁcant stromal penetration. How-
ever, when comparing the eﬀectiveness
of the trans-epithelial treatments, one
must consider the riboﬂavin applica-
tion time. In the present study, it
should be noted that the St Thomas’/
Cardiﬀ Iontophoresis protocol B,
which involves two 5-min iontophore-
sis-assisted deliveries of Ricrolin+ with
a 15-min soakage time in between, has
a similar riboﬂavin application time to
that of the Ricrolin TE, Mediocross TE
and St Thomas’/Cardiﬀ Iontophoresis
protocol A treatments but lasts three
times longer than the Paracel/Vibex
treatment and six times longer than the
Ricrolin+ and ionto treatment.
Although it cannot be determined from
this study whether the incorporation of
a longer soakage time in the Paracel/
Vibex and Ricrolin+ and ionto treat-
ments would signiﬁcantly improve stro-
mal riboﬂavin penetration, the results
do indicate that a longer iontophoresis
time as well as a longer soakage time
results in more eﬃcacious trans-epithe-
lial stromal riboﬂavin absorption. Fur-
ther studies are needed to determine
the optimum period of riboﬂavin soak-
age time and iontophoretic dosage for
trans-epithelial riboﬂavin delivery, but
clearly a modiﬁcation of the ion-
tophoretic trans-epithelial technique
oﬀers the most promise for epithe-
lium-on CXL.
Although the St Thomas’/Cardiﬀ
protocol B was the most eﬀective
trans-epithelial delivery protocol
tested, it was signiﬁcantly less eﬀective
at delivering riboﬂavin to the stroma
than the standard epithelium-oﬀ
method. However, it should be noted
that the eﬀectiveness of the 2-min
saline rinse (used following trans-ep-
ithelial treatments) as a means of
removing riboﬂavin from the intact
epithelium has not yet been validated,
and it is possible that the saline rinse
may itself cause a loss or dilution of
riboﬂavin within the anterior stroma.
As stromal riboﬂavin uptake and oxy-
gen diﬀusion are hindered by the pres-
ence of an intact epithelium and the
epithelium itself (along with any ribo-
ﬂavin that might be contained within
it) will absorb UVA light, it is likely
that the eﬃcacy of trans-epithelial
CXL will be less than that of the epi-
oﬀ technique. However, it is not yet
clear exactly what stromal concentra-
tion of riboﬂavin is needed to ensure
suﬃcient cross-linking for corneal sta-
bilization.
Based on the results presented in
this study and the potential patient
beneﬁts of trans-epithelial CXL over
the standard epithelium-oﬀ technique
in terms of patient comfort, speed of
visual recovery and safety, the St
Thomas’/Cardiﬀ Iontophoresis proto-
col B appears to be a promising new
alternative to the standard treatment.
Furthermore, as the thickness of the
epithelium in human corneas is less
than that of the porcine cornea
(~50 lm (Reinstein et al. 2008) and
90 lm, respectively), the stromal pen-
etration with our modiﬁed ion-
tophoresis protocol may be even
greater in practice than shown here
experimentally. Comparative clinical
studies are warranted to assess the
eﬃcacy of this protocol on kerato-
conus stabilization.
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